Table 1.
Baseline characteristic of PPI and non-PPI users.
| PPI (n = 297,099) | non-PPI (n = 3,125,594) | P-Value | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Gender | 0.0043 | ||||
| Female | 129,900 | 43.72% | 1,375,250 | 43.99% | |
| Male | 167,199 | 56.28% | 1,750,692 | 56.01% | |
| Age | <.0001 | ||||
| 20–30 | 37,209 | 12.52% | 623,753 | 19.95% | |
| 31–40 | 57,072 | 19.21% | 690,853 | 22.10% | |
| 41–50 | 68,021 | 22.90% | 720,217 | 23.04% | |
| 51–60 | 66,238 | 22.29% | 568,056 | 18.17% | |
| 61–70 | 38,407 | 12.93% | 276,260 | 8.84% | |
| 71–80 | 20,248 | 6.82% | 149,150 | 4.77% | |
| ≥81 | 9,904 | 3.33% | 97,653 | 3.12% | |
| Mean (SD) | 49.17 (15.63) | 45.38 (16.02) | <.0001 | ||
| Median (IQR) | 49 (23) | 44 (22) | <.0001 | ||
| Comorbidities | |||||
| Cancer | 13,150 | 4.43% | 50,087 | 1.60% | <.0001 |
| Diabetes Mellitus | 28,708 | 9.66% | 128,694 | 4.12% | <.0001 |
| End-Stage Renal Disease | 4,507 | 1.52% | 11,550 | 0.37% | <.0001 |
| Cirrhosis of Liver | 5,677 | 1.91% | 4,397 | 0.14% | <.0001 |
| Autoimmune Disorders | |||||
| Overall | 2926 | 0.98% | 7592 | 0.24% | <.0001 |
| Systemic | 1858 | 0.63% | 4635 | 0.15% | <.0001 |
| Organ-specific | 1075 | 0.36% | 2973 | 0.1% | <.0001 |
PPI, proton pump inhibitors.